TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22989293

Group type: EXPERIMENTAL
Intervention: Presence of atherosclerotic renal artery stenosis (ARAS) >50%
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Severity of ARAS
Number of subjects: 37

Group type: COMPARATOR
Intervention: Presence of ARAS
Number of subjects: 37

Group type: COMPARATOR
Intervention: Presence and extent of late gadolinium enhancement (myocardial fibrosis)
Number of subjects: 37

Group type: COMPARATOR
Intervention: End diastolic volume
Number of subjects: 37

Group type: COMPARATOR
Intervention: Left ventricular mass index
Number of subjects: 37

Group type: COMPARATOR
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Presence of ischemic pattern of late enhancement
Number of subjects: 37
Study: 20534140

Group type: EXPERIMENTAL
Intervention: Individualized physiotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard exercise protocol
Number of subjects: 90
Study: 17714851

Group type: EXPERIMENTAL
Intervention: Instructor-based course (3-hour training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-training using a poster, manikin, and training AED
Number of subjects: 30
Study: 15598949

Group type: EXPERIMENTAL
Intervention: COPP-ABVD
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: BEACOPP
Number of subjects: 75
Study: 12860772

Group type: EXPERIMENTAL
Intervention: 20 mg/d aripiprazole
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 30 mg/d aripiprazole
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 6 mg/d risperidone
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 20 mg/d aripiprazole and 6 mg/d risperidone
Number of subjects: 404
Study: 10788759

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8934305

Group type: EXPERIMENTAL
Intervention: Cocaine use detected through hair analysis
Number of subjects: 615
Study: 1860135

Group type: EXPERIMENTAL
Intervention: Chocolate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6614419

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.5-2 mg p.o. the evening before operation (Group 1)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.5-2 mg p.o. the evening before and the morning of operation (Group 2)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Lormetazepam 2-2.5 mg p.o. the same time as Group 2 (Group 3)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg p.o. the evening before operation and pethidine 50-100 mg combined with promethazine 25 mg i.m. 60 min before surgery (Group 4)
Number of subjects: 128
Study: 30914170

Group type: EXPERIMENTAL
Intervention: Higher level of male provision
Number of subjects: 108
Study: 27423222

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 21
Study: 26603558

Group type: EXPERIMENTAL
Intervention: Early intravitreal betamethasone injection (early-IVB)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Delayed intravitreal betamethasone injection (delayed-IVB)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Early-IVB
Number of subjects: 97

Group type: COMPARATOR
Intervention: Delayed-IVB
Number of subjects: 97
Study: 24374073

Group type: EXPERIMENTAL
Intervention: Endostatin combined with radiotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 80
Study: 23529990

Group type: EXPERIMENTAL
Intervention: Propolis extract (165 μmol artepillin C and 150 μmol other polyphenols per day for 3 months)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Propolis extract
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Laxative treatment prior to endoscopic biopsy
Number of subjects: 31
Study: 19674427

Group type: EXPERIMENTAL
Intervention: Premier Hospital Quality Incentive Demonstration (PHQID) program
Number of subjects: 6723928
Study: 18277517

Group type: EXPERIMENTAL
Intervention: Coherent context
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incoherent context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informative local properties
Number of subjects: 0
Study: 15741420

Group type: EXPERIMENTAL
Intervention: Homeopathic preparation of common allergens
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12212923

Group type: EXPERIMENTAL
Intervention: zidovudine/lamivudine/indinavir (induction phase)
Number of subjects: 366

Group type: COMPARATOR
Intervention: zidovudine/lamivudine (maintenance phase)
Number of subjects: 366

Group type: COMPARATOR
Intervention: zidovudine/indinavir (maintenance phase)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Adherence of 80% or greater
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Adherence <80%
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Poor adherence (two or more severe adverse events)
Number of subjects: 366
Study: 9671428

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.2 microg/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.5 microg/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenoldopam (1.0 microg/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenoldopam (all doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gonioscopy
Number of subjects: 12
Study: 8747563

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) mivacurium 0.15 mg/kg with stable general anesthesia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single bolus administration of mivacurium
Number of subjects: 36
Study: 2468447

Group type: EXPERIMENTAL
Intervention: 5% albumin infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10% low MW hydroxyethyl starch (pentastarch) infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 796485

Group type: EXPERIMENTAL
Intervention: Cephacetrile (CEC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cefazolin (CEZ)
Number of subjects: 101
Study: 31299400

Group type: EXPERIMENTAL
Intervention: Complex polypharmacy (use of ≥3 BD medications)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Non-adherence
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Comorbid social or generalized anxiety disorder
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Bipolar Disorder I vs. II
Number of subjects: 482
Study: 29061630

Group type: EXPERIMENTAL
Intervention: Usual care plus biopsychosocial intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 25481791

Group type: EXPERIMENTAL
Intervention: Olaparib plus chemotherapy (paclitaxel and carboplatin)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Chemotherapy alone (paclitaxel and carboplatin)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Olaparib plus chemotherapy
Number of subjects: 162
Study: 23668681

Group type: EXPERIMENTAL
Intervention: High-dose ciliary neurotrophic factor implant
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Low-dose ciliary neurotrophic factor implant
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor treatment
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 133
Study: 21887905

Group type: EXPERIMENTAL
Intervention: Sublingual piroxicam 40 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19004023

Group type: EXPERIMENTAL
Intervention: Screening arm (32,000 men)
Number of subjects: 80000

Group type: COMPARATOR
Intervention: Control arm (48,000 men)
Number of subjects: 80000

Group type: EXPERIMENTAL
Intervention: Interval cancers
Number of subjects: 80000
Study: 16719196

Group type: EXPERIMENTAL
Intervention: Preoperative relaxation training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Routine preoperative information
Number of subjects: 49
Study: 15570646

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg po bid
Number of subjects: 43
Study: 11529362

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (Kenacort A) injection on the left side after tonsillectomy and uvulopalatopharyngoplasty
Number of subjects: 48
Study: 9589245

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7819709

Group type: EXPERIMENTAL
Intervention: Microdroplet insemination with sperm:oocyte ratios ranging from 2000 to 10,000 motile sperm:1 oocyte
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Microdroplet insemination with sperm:oocyte ratios of 2000-4000:1 for male-factor sperm with one defect
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Microdroplet insemination with sperm:oocyte ratios of 8000-10,000:1 for male-factor sperm with two or three defects
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Microdroplet insemination
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 102
Study: 2644175

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1350
Study: 1151895

Group type: EXPERIMENTAL
Intervention: Two task-related warm-up treatments
Number of subjects: 105

Group type: COMPARATOR
Intervention: One condition of no warm-up
Number of subjects: 105
Study: 31483191

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention including an informative video, a brochure about ACP, and a guided discussion about EOL wishes
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 108
Study: 30826452

Group type: EXPERIMENTAL
Intervention: Intensive Reduction of Vascular Risk factors (IRVR) with blood pressure and cholesterol reduction
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Exercise training (EX)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: IRVR + EX
Number of subjects: 640

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 640
Study: 27924779

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 26405668

Group type: EXPERIMENTAL
Intervention: Nebulized sodium hyaluronate (NHA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroid spray (ICS) 200 µg bid
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both ICS and NHA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Open-label nebulized saline solution (NS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All treatment groups (NHA, ICS, ICS + NHA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 80
Study: 22715064

Group type: EXPERIMENTAL
Intervention: Elastic-resistance-training and lifestyle-activity intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 21478142

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD) 3 × 500 mg/day
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD)
Number of subjects: 256
Study: 18645741

Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 56
Study: 17052581

Group type: EXPERIMENTAL
Intervention: Bolus of fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: Infusion of alfentanil
Number of subjects: 40
Study: 12608473

Group type: EXPERIMENTAL
Intervention: Biennial H‐II screening program
Number of subjects: 24465

Group type: COMPARATOR
Intervention: Single FS+H‐II screening
Number of subjects: 24465
Study: 10381854

Group type: EXPERIMENTAL
Intervention: Very low fat diet (fat intake <=20% resting energy expenditure)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Low fat diet from the National Cholesterol Education Program
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Resting energy expenditure-fat diet + simvastatin 10mg daily
Number of subjects: 126

Group type: COMPARATOR
Intervention: National Cholesterol Education Program step 2 diet + simvastatin 10mg daily
Number of subjects: 126
Study: 8689858

Group type: EXPERIMENTAL
Intervention: Acarbose, 100 mg t.d.s. for 16 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 18
Study: 2199743

Group type: EXPERIMENTAL
Intervention: myringotomy with adenoidectomy
Number of subjects: 46

Group type: COMPARATOR
Intervention: myringotomy without adenoidectomy
Number of subjects: 46
Study: 7037664

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure breathing (PEEP) during exercise
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure breathing (PEEP) post-exercise
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normal exercise tests (control)
Number of subjects: 5
Study: 31694495

Group type: EXPERIMENTAL
Intervention: Aprepitant oral suspension (125 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Aprepitant capsule (125 mg)
Number of subjects: 17
Study: 28412650

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus evacetrapib 130 mg
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 366

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg plus placebo
Number of subjects: 366
Study: 25416687

Group type: EXPERIMENTAL
Intervention: Docetaxel/oxaliplatin/5‐FU (TEF)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Docetaxel/oxaliplatin (TE)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Docetaxel/oxaliplatin/capecitabine (TEX)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Febrile neutropenia
Number of subjects: 248

Group type: COMPARATOR
Intervention: Common grade 3/4 AEs
Number of subjects: 248
Study: 24554598

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23075177

Group type: EXPERIMENTAL
Intervention: Linezolid therapy starting immediately at a dose of 600 mg per day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Linezolid therapy starting after 2 months at a dose of 600 mg per day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Linezolid therapy at a dose of 300 mg per day after second randomization
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Linezolid therapy at a dose of 600 mg per day after second randomization
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Linezolid therapy (both dosages)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Linezolid therapy
Number of subjects: 41
Study: 19879595

Group type: EXPERIMENTAL
Intervention: 1% lactulose
Number of subjects: 28

Group type: COMPARATOR
Intervention: 1% dextrose (control)
Number of subjects: 28
Study: 17019624

Group type: EXPERIMENTAL
Intervention: Risperidone (1.37 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 15574481

Group type: EXPERIMENTAL
Intervention: AB-lock containing vancomycin or ceftazidime
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: AB-lock
Number of subjects: 46
Study: 11913107

Group type: EXPERIMENTAL
Intervention: Near-total thyroidectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine radioiodide ablative therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consensus guidelines
Number of subjects: 0
Study: 14528702

Group type: EXPERIMENTAL
Intervention: Complementary therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 0
Study: 7576677

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) clonidine (loading dose of 4 micrograms/kg in 20 minutes at anesthesia induction, followed by a continuous infusion of 2 micrograms/kg/h until the end of surgery)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 402
Study: 2895564

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (5-ISMN) 60 mg, Imdur, once daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 31095678

Group type: EXPERIMENTAL
Intervention: ASHS‐LIA (Age‐related scattered hypofluorescent spots on late‐phase indocyanine green angiography)
Number of subjects: 187

Group type: COMPARATOR
Intervention: No ASHS‐LIA
Number of subjects: 187
Study: 28385919

Group type: EXPERIMENTAL
Intervention: Higher protein (HIGH: 1,103 kcal/day, 133 g protein/day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Moderate protein (MOD: 974 kcal/day, 84 g protein/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Carbohydrate‐based low protein control (CON: 1,042 kcal/day, 7 g protein/day)
Number of subjects: 63
Study: 26233715

Group type: EXPERIMENTAL
Intervention: Single 2.0‐mm locking miniplate (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single rigid 2.3‐mm plate (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single lag screw (Group C)
Number of subjects: 30
Study: 23718024

Group type: EXPERIMENTAL
Intervention: Botulotoxin preparation (Disport) injected between internal and external anal sphincter portions, 90 units, 5-15 days preoperatively.
Number of subjects: 83

Group type: COMPARATOR
Intervention: No botulotoxin injection (control group).
Number of subjects: 83
Study: 21238983

Group type: EXPERIMENTAL
Intervention: T-piece ventilation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Self-inflating bag (SIB) ventilation
Number of subjects: 80
Study: 18667054

Group type: EXPERIMENTAL
Intervention: 100 mg 5-Loxin daily for 90 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 250 mg 5-Loxin daily for 90 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 21190858

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections combined with comprehensive rehabilitation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study: 16201068

Group type: EXPERIMENTAL
Intervention: Fixation of the greater omentum to the peritoneum
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-fixation of the greater omentum
Number of subjects: 49
Study: 12039463

Group type: EXPERIMENTAL
Intervention: Crinone 8% (n = 73) vaginally once daily
Number of subjects: 126

Group type: COMPARATOR
Intervention: Utrogest (n = 53) vaginally three times daily (600 mg)
Number of subjects: 126
Study: 10756833

Group type: EXPERIMENTAL
Intervention: Implant application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up cooperation regarding oral hygiene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphological stability evaluation through clinical X-ray parameters
Number of subjects: 0
Study: 7989980

Group type: EXPERIMENTAL
Intervention: SPECT and CT/MRI registration in patients infused with 10 mCi of 131I-CC49 prior to staging laparotomy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SPECT imaging following radioimmunotherapy with 131I-CC49
Number of subjects: 24
Study: 3289111

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PVC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both PVC and cimetidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PVC and cimetidine
Number of subjects: 60
Study: 11174772

Group type: EXPERIMENTAL
Intervention: Primary CEA alone
Number of subjects: 10561

Group type: EXPERIMENTAL
Intervention: Preoperative antiplatelet agents
Number of subjects: 10561

Group type: EXPERIMENTAL
Intervention: Intraoperative heparin
Number of subjects: 10561

Group type: EXPERIMENTAL
Intervention: Patch angioplasty
Number of subjects: 10561

Group type: EXPERIMENTAL
Intervention: Repeat procedures
Number of subjects: 10561

Group type: EXPERIMENTAL
Intervention: CEA combined with coronary artery bypass grafting
Number of subjects: 10561
Study: 31344011

Group type: EXPERIMENTAL
Intervention: Thigh-compression shorts at 6-15 mm Hg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Thigh-compression shorts at 0 mm Hg (control)
Number of subjects: 12
Study: 30193809

Group type: EXPERIMENTAL
Intervention: Self-ankle mobilization with movement
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Self-ankle mobilization with movement with a 10° inclined board
Number of subjects: 28
Study: 27096858

Group type: EXPERIMENTAL
Intervention: Oral carbohydrate supplement (12.5% carbohydrate, 400ml six hours and 200ml two hours before surgery)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group with fasting prescription 6-8 hours before surgery
Number of subjects: 27
Study: 24450319

Group type: EXPERIMENTAL
Intervention: High dose frequency (HDF) - five 1‐hr sessions per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose frequency (LDF) - one 1‐hr session per week
Number of subjects: 0
Study: 23427390

Group type: EXPERIMENTAL
Intervention: Traditional Chinese spinal orthopedic manipulation (TCSOM), 5 treatments
Number of subjects: 210

Group type: COMPARATOR
Intervention: Pinaverium bromide Dicetel (PBD)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: TCSOM
Number of subjects: 210
Study: 20304982

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine 0.5%
Number of subjects: 80
Study: 16899479

Group type: EXPERIMENTAL
Intervention: Topical beclometasone
Number of subjects: 75

Group type: COMPARATOR
Intervention: Dexamethasone on lymphocyte proliferation stimulated by PHA
Number of subjects: 75
Study: 15177704

Group type: EXPERIMENTAL
Intervention: Higher levels of TSH
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Exclusion of individuals with TSH levels suspect for thyroid disorder (n=2) or who were on thyroid replacement (n=3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Control for mood status
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No interaction between age and TSH on cognition
Number of subjects: 120
Study: 11586012

Group type: EXPERIMENTAL
Intervention: 30 mg elemental zinc
Number of subjects: 332

Group type: COMPARATOR
Intervention: 100 mg minocycline
Number of subjects: 332